BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Garcia-Lezana T, Lopez-Canovas JL, Villanueva A. Signaling pathways in hepatocellular carcinoma. Adv Cancer Res 2021;149:63-101. [PMID: 33579428 DOI: 10.1016/bs.acr.2020.10.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Li Z, Gao H, Zhang X, Liu Q, Chen G. Mutational and transcriptional alterations and clinicopathological factors predict the prognosis of stage I hepatocellular carcinoma: Prediction of stage I HCC prognosis. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02496-3] [Reference Citation Analysis]
2 Haque A, Sahu V, Lombardo JL, Xiao L, George B, Wolff RA, Morris JS, Rashid A, Kopchick JJ, Kaseb AO, Amin HM. Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development. J Hepatocell Carcinoma 2022;9:823-37. [PMID: 35996397 DOI: 10.2147/JHC.S368208] [Reference Citation Analysis]
3 Alharbi KS, Javed Shaikh MA, Afzal O, Alfawaz Altamimi AS, Almalki WH, Alzarea SI, Kazmi I, Al-Abbasi FA, Singh SK, Dua K, Gupta G. An overview of epithelial growth factor receptor (EGFR) inhibitors in cancer therapy. Chem Biol Interact 2022;366:110108. [PMID: 36027944 DOI: 10.1016/j.cbi.2022.110108] [Reference Citation Analysis]
4 Cai G, Zhu J, Ning D, Li G, Zhang Y, Xiong Y, Liang J, Yu C, Chen X, Liang H, Ding Z. A Novel hepatocellular carcinoma specific hypoxic related signature for predicting prognosis and therapeutic responses. Front Immunol 2022;13:997316. [DOI: 10.3389/fimmu.2022.997316] [Reference Citation Analysis]
5 Mattos ÂZ, Debes JD, Vogel A, Arrese M, Revelo X, Pase THS, Manica M, Mattos AA. Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy? . World J Gastroenterol 2022; 28(28): 3595-3607 [DOI: 10.3748/wjg.v28.i28.3595] [Reference Citation Analysis]
6 Ma P, Zou C, Xia S. Oncogenic signaling pathway mediated by Notch pathway-related genes induces immunosuppression and immunotherapy resistance in hepatocellular carcinoma. Immunogenetics 2022. [PMID: 35895154 DOI: 10.1007/s00251-022-01273-6] [Reference Citation Analysis]
7 Cheng Z, Yu R, Li L, Mu J, Gong Y, Wu F, Liu Y, Zhou X, Zeng X, Wu Y, Sun R, Xiang T. Disruption of ZNF334 promotes triple-negative breast carcinoma malignancy through the SFRP1/ Wnt/β-catenin signaling axis. Cell Mol Life Sci 2022;79:280. [PMID: 35507080 DOI: 10.1007/s00018-022-04295-1] [Reference Citation Analysis]
8 Qin J, Guo C, Yang L, Liang X, Jiao A, Lai KP, Yang B. Bioinformatics and in-silico findings reveal medical features and pharmacological targets of biochanin A against colorectal cancer and COVID-19. Bioengineered 2021;12:12461-9. [PMID: 34931923 DOI: 10.1080/21655979.2021.2005876] [Reference Citation Analysis]
9 Icard P, Simula L, Wu Z, Berzan D, Sogni P, Dohan A, Dautry R, Coquerel A, Lincet H, Loi M, Fuks D. Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma? Drug Resist Updat 2021;:100790. [PMID: 34924279 DOI: 10.1016/j.drup.2021.100790] [Reference Citation Analysis]
10 He J, Zhang W, Zhou X, Yan W, Wang Z. Aloin induced apoptosis by enhancing autophagic flux through the PI3K/AKT axis in osteosarcoma. Chin Med 2021;16:123. [PMID: 34819120 DOI: 10.1186/s13020-021-00520-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Pu J, Li W, Wang A, Zhang Y, Qin Z, Xu Z, Wang J, Lu Y, Tang Q, Wei H. Long non-coding RNA HOMER3-AS1 drives hepatocellular carcinoma progression via modulating the behaviors of both tumor cells and macrophages. Cell Death Dis 2021;12:1103. [PMID: 34815380 DOI: 10.1038/s41419-021-04309-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]